Cor Vasa 2012, 54(9-10):e305-e313 | DOI: 10.1016/j.crvasa.2012.08.003

Resistance to antiplatelet treatment: The clinical relevance of platelet function assays

Jiří Plášeka,b,*, Miroslav Homzaa,b, Jaromír Gumulecc, Markéta Ryzíc, Radovan Stančíka, David Šipulaa
a Kardiovaskulární oddělení, Fakultní nemocnice Ostrava, Ostrava, Česká republika
b Lékařská fakulta Ostravské univerzity, Ostrava, Česká republika
c Ústav klinické hematologie, Fakultní nemocnice Ostrava, Ostrava, Česká republika

Funkční vyšetření trombocytů zatím není rutinní vyšetřovací metodou v kardiologii. Vyšetření by mělo selektovat pacienty se zvýšenou reziduální reaktivitou trombocytů (high on-treatment platelet reacti-vity - HPR). Zvýšená reziduální reaktivita trombocytů je zřejmým, ačkoliv ne jediným, rizikovým faktorem aterotrombózy. Existuje mnoho dalších faktorů (aktivace trombocytů, endoteliální dysfunkce, ruptura aterosklerotického plátu) ovlivňujících vývoj aterotrombózy. Protidestičková léčba je cílena především na snížení úrovně aktivace trombocytů. V neposlední řadě je třeba zohlednit unikátní farmakodynamiku a farmakokinetiku každé účinné látky a farmakogenetický profil recipienta. Cílem naší práce je shrnout dosavadní poznatky a podat ucelenou informaci o pozitivech, ale i rizicích hodnocení funkčního vyšetření trombocytů v kardiologii.

Keywords: Aspirinová, clopidogrelová rezistence; Funkční vyšetření trombocytů; Vysoká reziduální reaktivita

Received: April 6, 2012; Revised: August 3, 2012; Accepted: August 8, 2012; Published: September 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Plášek J, Homza M, Gumulec J, Ryzí M, Stančík R, Šipula D. Resistance to antiplatelet treatment: The clinical relevance of platelet function assays. Cor Vasa. 2012;54(9-10):e305-313. doi: 10.1016/j.crvasa.2012.08.003.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Antithrombotic Trialists' Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ 324 (7329) (2002) 71-86. Go to original source... Go to PubMed...
    2. E.L. de Oliviera, L.B. Deepak, Clinical evaluation of clopidogrel across the whole spectrum of indications: primary and secondary prevention of coronary artery disease, European Heart Journal 8 (2006) G10-G14. Go to original source...
    3. G.J. Hankey, J.W. Eikelboom, Aspirin resistence, BMJ 328 (2004) 477-479. Go to original source... Go to PubMed...
    4. A. McNicol, S.J. Israels, Platelets and anti-platelet therapy, Journal of Pharmacological Sciences 93 (2003) 381-396. Go to original source... Go to PubMed...
    5. G.A. FitzGerald, Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists, American Journal of Cardiology 68 (7) (1991) 11B-15B. Go to original source... Go to PubMed...
    6. P.M. Rothwell, M. Wilson, C.E. Elwin, et al., Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials, Lancet 376 (9754) (2010) 1741-1750. Go to original source... Go to PubMed...
    7. F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, et al., Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. New England Journal of Medicine 345 (25) (2001) 1809-1817. Go to original source... Go to PubMed...
    8. C. Patrono, B. Coller, G.A. FitzGerald, et al., Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest 126 (2004) 234S-264S. Go to original source... Go to PubMed...
    9. C. Patrono, B. Coller, J.E. Dalen, et al., Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119 (2001) 39S-63S. Go to original source... Go to PubMed...
    10. R. Ross, Atherosclerosis - an inflammatory disease, New England Journal of Medicine 340 (2) (1999) 115-126. Go to original source... Go to PubMed...
    11. N. Faraday, L.R. Yanek, R. Mathias, et al., Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1, Circulation 115 (19) (2007) 2490-2496. Go to original source... Go to PubMed...
    12. P.C. Kam, C.M. Nethery, The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments, Anaesthesia 58 (2003) 28-35. Go to original source... Go to PubMed...
    13. P.C. Cannon, Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial), American Journal of Cardiology 90 (7) (2002) 760-762. Go to original source... Go to PubMed...
    14. S.R. Steinhubl, K. Kottke-Marchant, D.J. Moliterno, et al., Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention, Circulation 100 (19) (1999) 1977-1982. Go to original source...
    15. E.J. Topol, A.M. Lincoff, D.J. Kereiakes, et al., Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization, American Journal of Medicine 113 (1) (2002) 1-6. Go to original source... Go to PubMed...
    16. J. Maclouf, G. Folco, C. Patrono, Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease, Thrombosis and Haemostasis 79 (4) (1998) 691-705. Go to original source... Go to PubMed...
    17. S.S. Barbieri, B.B. Weksler, Tobacco smoke cooperates with interleukin-1beta to alter beta-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo, FASEB Journal 21 (8) (2007) 1831-1843. Go to original source... Go to PubMed...
    18. N. Zimmermann, A. Wenk, U. Kim, et al., Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery, Circulation 108 (5) (2003) 542-547. Go to original source... Go to PubMed...
    19. C.J. O'Donnell, M.G. Larson, D. Feng, et al., Framingham Heart Study. Genetic and environmental contributions to platelet aggregation: the Framingham heart study, Circulation 103 (25) (2001) 3051-3056. Go to original source...
    20. J.A. Cambria-Kiely, P.J. Gandhi, Aspirin resistance and genetic polymorphisms, Journal of Thrombosis and Thrombolysis 14 (1) (2002) 51-58. Go to original source... Go to PubMed...
    21. K.A. Schwartz, D.E. Schwartz, K. Ghosheh, et al., Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction, American Journal of Cardiology 95 (8) (2005) 973-975. Go to original source... Go to PubMed...
    22. F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, et al., Cyclooxygenase inhibitors and the antiplatelet effects of aspirin, New England Journal of Medicine 345 (25) (2001) 1809-1817. Go to original source... Go to PubMed...
    23. M.L. Capone, M.G. Sciulli, S. Tacconelli, et al., Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects, Journal of the American College of Cardiology 45 (8) (2005) 1295-1301. Go to original source... Go to PubMed...
    24. G.J. Hankey, J.W. Eikelboom, Aspirin resistence, Lancet 367 (2006) 607-617. Go to original source... Go to PubMed...
    25. J.W. Eikelboom, J. Hirsh, J.I. Weitz, et al., Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events, Circulation 105 (14) (2002) 1650-1655. Go to original source... Go to PubMed...
    26. T.A. Nguyen, J.G. Diodati, C. Pharand, Resistance to clopidogrel: a review of the evidence, Journal of the American College of Cardiology 45 (8) (2005) 1157-1164. Go to original source... Go to PubMed...
    27. T. Simon, C. Verstuyft, M. Mary-Krause, et al., French registry of acute ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) investigators. Genetic determinants of response to clopidogrel and cardiovascular events, New England Journal of Medicine 360 (4) (2009) 363-375. Go to original source... Go to PubMed...
    28. A.R. Shuldiner, K.P. Bilden, A. Gandhi, et al., Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy, Journal of the American Medical Association 302 (2009) 849-857. Go to original source... Go to PubMed...
    29. J.L. Mega, W. Hochholzer, A.L. Benin Frelinger 3rd, et al., Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease, Journal of the American Medical Association 306 (2011) 2221-2228. Go to original source... Go to PubMed...
    30. M.V. Holmes, P. Perel, T. Shah, et al., CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events. A systematic review and meta-analysis, Journal of the American Medical Association 306 (2011) 2704-2714. Go to original source... Go to PubMed...
    31. D.L. Bhatt, B.L. Cryer, C.F. Contant, et al., COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease, New England Journal of Medicine 363 (20) (2010) 1909-1917. Go to original source...
    32. V.L. Serebruany, M.G. Midei, A.I. Malinin, et al., Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study, Archives of Internal Medicine 164 (18) (2004) 2051-2057. Go to original source... Go to PubMed...
    33. S. Riondino, N. Petrini, L. Donato, et al., Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients, Journal of Thrombosis and Thrombolysis 28 (2) (2009) 151-155. Go to original source... Go to PubMed...
    34. M. Gilard, B. Arnaud, J.C. Cornily, et al., Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study, Journal of the American College of Cardiology 51 (3) (2008) 256-260. Go to original source... Go to PubMed...
    35. J.P. Collet, J.W. Werkum, Individualised antiplatelet therapy - is there a role for platelet function testing in routine clinical practice? European Cardiology 6 (1) (2010) 41-49. Go to original source...
    36. M.J. Quinn, E.F. Plow, E.J. Topol, Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?, Circulation 106 (3) (2002) 379-385. Go to original source... Go to PubMed...
    37. J.W. van Werkum, W.B. Gerritsen, J.C. Kelder, et al., Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial, Netherlands Heart Journal 15 (11) (2007) 375-381. Go to original source... Go to PubMed...
    38. A. Kastrati, J. Mehilli, F.J. Neumann, et al., Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial, Journal of the American Medical Association 295 (2006) 1531-1538. Go to original source... Go to PubMed...
    39. G. Campo, L. Fileti, N. de Cesare, et al., 3T/2R Investigators, Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy, Journal of the American College of Cardiology 56 (2010) 1447-1455. Go to original source... Go to PubMed...
    40. T. Cuisset, C. Frere, J. Quilici, et al., Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. Journal of the American College of Cardiology Interventions 1 (2008) 649-653. Go to original source... Go to PubMed...
    41. N.J. Breet, J.W. van Werkum, H.J. Bouman, et al., Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation, Journal of the American Medical Association 303 (8) (2010) 754-762. Go to original source... Go to PubMed...
    42. P.A. Gurbel, K.P. Bliden, W. Samara, et al., Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study, Journal of the American College of Cardiology 46 (2005) 1827-1832. Go to original source... Go to PubMed...
    43. P. Barragan, J.L. Bouvier, P.O. Roquebert, et al., Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation, Catheterization and Cardiovascular Interventions 59 (2003) 295-302. Go to original source... Go to PubMed...
    44. S. Kundu, E. Heilman, R. Sio, et al., Description of an in vitro platelet function analyzer-PFA-100, Seminars in Thrombosis and Haemostasis 21 (suppl 2) (1995) 106-112. Go to original source...
    45. J. Koessler, A.L. Kobsar, M.S. Rajkovic, et al., The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition, Platelets 22 (1) (2011) 19-25. Go to original source... Go to PubMed...
    46. J.M. Siller-Matula, G. Christ, I.M. Lang, et al., Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay, Journal of Thrombosis and Haemostasis 8 (2) (2010) 351-359. Go to original source... Go to PubMed...
    47. D. Sibbing, S. Braun, T. Morath, et al., Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis, Journal of the American College of Cardiology 53 (10) (2009) 849-856. Go to original source... Go to PubMed...
    48. D. Sibbing, S. Braun, S. Jawansky, et al., Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment, Thrombosis and Haemostasis 99 (1) (2008) 121-126. Go to original source... Go to PubMed...
    49. K.P. Dichiara Bliden, U.S. Tantry, S.K. Chaganti, et al., Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients, Platelets 18 (6) (2007) 414-423. Go to original source... Go to PubMed...
    50. M.J. Price, P.B. Berger, P.S. Teirstein, et al., Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. The GRAVITAS randomized trial, Journal of the American Medical Association 305 (2011) 1097-1105. Go to original source... Go to PubMed...
    51. D. Trenk, G.W. Stone, M. Gawaz, et al., A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study, Journal of the American College of Cardiology (2012) Epub ahead of print. Go to original source... Go to PubMed...
    52. R.S. Wright, J.L. Anderson, C.D. Adams, et al., 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation 123 (2011) 2022-2060. Go to original source...
    53. C.W. Hamm, J.P. Bassand, S. Agewall, et al., ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC), European Heart Journal 32 (2011) 2999-3054.
    54. S.D. Wiviott, E. Braunwald, C.H. McCabe, et al., TRITON-TIMI 38 Investigators, Prasugrel versus clopidogrel in patients with acute coronary syndromes, New England Journal of Medicine 357 (20) (2007) 2001-2015. Go to original source... Go to PubMed...
    55. P.A. Gurbel, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121 (10) (2010) 1188-1199. Go to original source... Go to PubMed...
    56. J.P. Collet, G. Cayla, T. Cuisset, et al., Randomized comparison of platelet function monitoring to adjust antiplatelet therapy vs standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose vs a monitoring-guided dose of Aspirin and Clopidogrel after DES implantation, and (2) treatment interruption vs continuation, 1 year after stenting (ARCTIC) study, American Heart Journal 161 (1) (2011) 5-12. Go to original source... Go to PubMed...
    57. D.J. Angiolillo, Applying platelet function testing in clinical practice: what are the unmet needs?, Journal of the American Medical Association 306 (11) (2011) 1260-1261. Go to original source... Go to PubMed...
    58. L. Wallentin, R.C. Becker, A. Budaj, et al., PLATO Investigators, A. Freij, M. Thorsén, Ticagrelor versus clopidogrel in patients with acute coronary syndromes, New England Journal of Medicine 361 (11) (2009) 1045-1057. Go to original source... Go to PubMed...
    59. D.J. Angiolillo, Unraveling myths of platelet function and genetic testing the road to making tailored antiplatelet therapy a reality, Journal of the American College of Cardiology 57 (25) (2011) 2484-2486. Go to original source... Go to PubMed...
    60. G. Montalescot, J.S. Hulot, J.P. Collet, Stent thrombosis: who's guilty?, European Heart Journal 30 (22) (2009) 2685-2688. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes